BioPharma Resources

Drug Trial Radar · NCT06091865

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

A Phase 3, Open Label, Randomized Study Comparing the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 × Anti-CD3 Bispecific Antibody, in Combination With CHOP (ODRO-CHOP) Versus Rituximab in Combination With CHOP (R-CHOP) in Previously Untreated Participants With Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3)

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 904 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

904

Planned (sponsor's estimate)

Start

Dec 13, 2023

Primary completion

Mar 30, 2028

Study completion Sep 12, 2029

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Oct 19, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study is focused on patients with Diffuse Large B-cell Lymphoma (DLBCL) that have not been treated before (called "previously untreated"). Patients with DLBCL that have come back after treatment (called "relapsed"), or have not responded to treatment (called "refractory"), can also participate in this study. This study will be made up of Part 1A, Part 1B, and Part 2.The aim of Part 1A and Part 1B of the study is to see how safe and tolerable the study drug in combination with chemotherapy is and to determine the dose and schedule of the study drug to be combined with chemotherapy in Part 2 of the study. The aim of Part 2 of the study is to see how effective the combination of the study drug with chemotherapy is in comparison with the combination of rituximab (the comparator drug), and chemotherapy, the current standard of care treatment approved for DLBCL. Standard of care means the usual medication expected and used when receiving treatment for a condition. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug when combined with chemotherapy * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects) * The impact from the study drug on quality of life and ability to complete routine daily activities

Conditions

  • Diffuse Large B-cell Lymphoma (DLBCL)

Interventions

  • OdronextamabDrug

    Odronextamab will be administered by intravenous (IV) infusion

  • RituximabDrug

    Rituximab will be administered IV, or subcutaneously (SC)

  • CyclophosphamideDrug

    Cyclophosphamide will be administered IV as part of chemotherapy

  • DoxorubicinDrug

    Doxorubicin will be administered IV as part of chemotherapy

  • VincristineDrug

    Vincristine will be administered IV as part of chemotherapy

  • Prednisone/PrednisoloneDrug

    Prednisone or prednisolone will be administered orally (PO) as part of chemotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose Limiting Toxicities (DLTs)Time frame: Up to 35 days
  2. Incidence of Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 2 years
  3. Severity of TEAEsTime frame: Up to 2 years
  4. Progression Free Survival (PFS), assessed by Independent Central Review (ICR)Time frame: Up to 5 years

Locations

195 sites in 21 countries. Site status is shown where the registry gives one.

  • Mayo Clinic - Arizona

    Scottsdale, Arizona · Recruiting

  • David Geffen School of Medicine at UCLA

    Los Angeles, California · Recruiting

  • University of California Irvine Medical Center

    Orange, California · Recruiting

  • UC Davis Comprehensive Cancer Center

    Sacramento, California · Withdrawn

  • Mayo Clinic Jacksonville

    Jacksonville, Florida · Recruiting

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center

    Indianapolis, Indiana · Recruiting

  • St Vincent Ascension at Peyton Manning Childrens Hospital

    Indianapolis, Indiana · Recruiting

  • Investigative Clinical Research of Indiana

    Noblesville, Indiana · Recruiting

  • University of Kentucky

    Lexington, Kentucky · Recruiting

  • University of Maryland Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

  • Henry Ford Health System

    Detroit, Michigan · Recruiting

  • Cancer and Hematology Centers of Western Michigan

    Grand Rapids, Michigan · Recruiting

  • Mayo Clinic - Rochester

    Rochester, Minnesota · Recruiting

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey · Recruiting

  • Stony Brook University Hospital

    Stony Brook, New York · Recruiting

  • Clinical Research Alliance Inc

    Westbury, New York · Withdrawn

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • East Carolina University

    Greenville, North Carolina · Recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • Center for Oncology and Blood Disorders

    Houston, Texas · Withdrawn

  • Community Cancer Trials of Utah

    Ogden, Utah · Recruiting

  • Prohealth Care Inc

    Waukesha, Wisconsin · Withdrawn

  • Liverpool Hospital

    Liverpool, New South Wales, Australia · Recruiting

  • Calvary Mater Newcastle

    Waratah, New South Wales, Australia · Recruiting

  • Icon Cancer Centre - Wesley

    Auchenflower, Queensland, Australia · Recruiting

  • Pindara Private Hospital

    Benowa, Queensland, Australia · Recruiting

  • Epworth Freemasons

    East Melbourne, Victoria, Australia · Recruiting

  • Medical University Graz

    Graz, Austria · Recruiting

  • Medical University of Vienna

    Vienna, Austria · Recruiting

  • Hanusch Krankenhaus

    Vienna, Austria · Recruiting

  • Klinikum Wels-Grieskirchen

    Wels, Austria · Recruiting

  • Landeskrankenhaus Hochsteiermark

    Leoben, Styria, Austria · Recruiting

  • Kepler University Hospital

    Linz, Upper Austria, Austria · Recruiting

  • Institut Jules Bordet

    Brussels, Belgium · Recruiting

  • AZ St.-Elisabeth Herentals vzw

    Herentals, Antwerp, Belgium · Recruiting

  • Centre Hospitalier Regional de Verviers

    Verviers, Liege, Belgium · Recruiting

  • Universitair Ziekenhuis (UZ) Gent/ Ghent University Hospital

    Ghent, Oost-Vlaanderen, Belgium · Recruiting

  • Algemeen Ziekenhuis AZ Delta

    Roeselare, West-Vlaanderen, Belgium · Recruiting

  • Instituto Nacional de Cancer Jose Alencar Gomes da Silva

    Rio de Janeiro, Brazil · Recruiting

Showing 40 of 195 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.